← Back to Search

Cancer Vaccine

mRNA-2736 for Multiple Myeloma

Phase 1

Waitlist Available

Research Sponsored by ModernaTX, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial tests a new drug to treat a blood cancer, to see if it's safe and how it affects people.

Eligible Conditions

Multiple Myeloma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants Experiencing Adverse Events

Secondary outcome measures

Area Under the Concentration-time Curve (AUC)

Area Under the Effect Concentration (AUEC)

Clinical Benefit Rate (CBR)

+6 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: mRNA-2736Experimental Treatment1 Intervention

Participants will receive mRNA-2736.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor

107 Previous Clinical Trials

61,378,125 Total Patients Enrolled

1 Trials studying Multiple Myeloma

200 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many medical centers in this city are administering the research trial?

"There are 13 different sites taking part in this medical trial, including the University of Miami Health System, Washington University Medical Center, and Memorial Sloan Kettering Cancer Center. Other locations are also available for enrollment."

Answered by AI

Has mRNA-2736 been granted regulatory approval by the FDA?

"mRNA-2736 has only had limited research done in terms of safety and efficacy, so it is ranked a 1 on our team's scale."

Answered by AI

Is this clinical experiment currently enrolling participants?

"According to clinicaltrials.gov, this particular medical research is not presently looking for participants. The post was initially published on July 12th 2023 and later updated on June 15th 2023. Although it isn't actively seeking volunteers now, there are 813 other studies that are currently enrolling candidates."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

2023. "mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05918250.